ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases
October 15, 2024Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme. -
Thrombolytic Science Granted US Patent on Novel Clot Dissolving Therapy, Complementing Patent Protection in Europe, Japan, China, Hong Kong, S.A.R., China, Mexico & CIS
October 29, 2021Thrombolytic Science, LLC (TSI) today announced the granting of a new patent by the USPTO. Most strokes and all heart attacks are caused by a blood clot blocking essential blood flow to a portion of the brain or heart.
Pharma Sources Insight January 2025
